Jakob Busch-Petersen

#NEWS: We continue to bolster our #cancer pipeline with an investment in a new NBE-Therapeutics AG R&D center in Basel. The CHF 27 million investment will further strengthen our antibody-drug conjugate (ADC) development. ADCs combine the specificity of antibodies with the therapeutic activity of cytotoxics, offering a promising, targeted treatment option for cancer. Learn more: https://bit.ly/42ba7qQ #ResearchCollaboration

2.486

18 Kommentare

Multivalency Key to a Potential First-in-Class Lp(a) Formation Inhibitor | https://lnkd.in/gEVeTc32 Eli Lilly and Company's muvalaplin (LY3473329) is the first selective, oral small molecule Lp(a) (lipoprotein(a)) formation inhibitor to enter the clinic. Mulvalaplin disrupts the formation of Lp(a), an established, genetically-determined risk factor for cardiovascular disease, by binding to multiple kringle domains of the precursor apo(a) protein through its trimeric structure. Eli Lilly recently announced positive results from its Ph. II study in adults with elevated Lp(a) levels, demonstrating dose-dependent reduction in Lp(a) levels with few adverse events. Read the story behind the compound on Drug Hunter | https://lnkd.in/gEVeTc32

215

3 Kommentare

Exciting news for the pharmaceutical industry! The 3 mm Multi-Nuclear Inverse CryoProbe (CP-MNI), with its high sensitivity and versatility, is an invaluable tool for the structural characterization of peptides, oligonucleotides, and natural products. Expect fast, reliable, and accurate results across various biology and pharmaceutical studies applications. Learn more: https://lnkd.in/dV-Jpryk #TIDES #NMR #Pharma #oligonucleotide #peptide

47

2 Kommentare

Verve is dedicated to developing transformative #geneediting medicines. We were thrilled to be selected once again to design cover art for ACS Publications. The latest issue of Analytical Chemistry features our latest publication on how top-down mass spectrometry combined with ion mobility separation was used to analytically interrogate #CRISPR guide RNA. Read more here: https://lnkd.in/e3vxRzbY

91

Evotec SE today announced that the Company has received a payment of US$ 25 m from Bristol Myers Squibb for scientific progress achieved within their strategic neuroscience partnership. The payment will advance further research and the partners’ joint pipeline of programs aimed at tackling neurogenerative diseases. Read the full press release to learn more- https://okt.to/nFh8cv #Neuroscience

40

1 Kommentar

Mass spectrometry for biomarker detection is powerful — but costly, complex and hard to scale. Learn how Oxford Nanopore is developing direct peptide detection for absolute quantification that’s simpler, faster and more accessible. Learn more: https://lnkd.in/eQX9TEEN

142

2 Kommentare